In vitro metabolism of obovatol and its effect on cytochrome P450 enzyme activities in human liver microsomes

Biopharmaceutics and Drug Disposition

Volumn 34, Issue 4, 2013, Pages 195-202

  Joo, Jeongmin ^a   Lee, Doohyun ^a   Wu, Zhexue ^a   Shin, Jung Hoon ^a   Lee, Hye Suk ^b   Kwon, Byoung Mog ^c   Huh, Tae Lin ^a   Kim, Yang Weon ^d   Lee, Su Jun ^d   Kim, Tae Wan ^a   Lee, Taeho ^a   Liu, Kwang Hyeon ^a  

^a Kyungpook National University   (South Korea)

^b The Catholic University of Korea   (South Korea)

^c Korea Research Institute of Bioscience and Biotechnology (KRIBB)   (South Korea)

^d Inje University College of Medicine   (South Korea)

Author keywords

drug interaction; glucuronidation; microsomes; obovatol; oxidation

Indexed keywords

CYTOCHROME P450; CYTOCHROME P450 2C19; DRUG METABOLITE; GLUCURONIDE; HYDROXYOBOVATOL; HYDROXYOBOVATOL OBOVATOL; MEPHENYTOIN HYDROXYLASE; OBOVATOL; OBOVATOL DIGLUCURONIDE; OBOVATOL GLUCURONIDE; OXYGENASE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE; UNCLASSIFIED DRUG; URIDINE DIPHOSPHATE GALACTOSE;

ARTICLE; CONTROLLED STUDY; DRUG METABOLISM; DRUG POTENCY; DRUG STRUCTURE; ENZYME ACTIVITY; ENZYME INHIBITION; HUMAN; IC 50; IN VITRO STUDY; LIQUID CHROMATOGRAPHY; LIVER MICROSOME METABOLISM; STRUCTURE ANALYSIS; TANDEM MASS SPECTROMETRY;

ARYL HYDROCARBON HYDROXYLASES; CHROMATOGRAPHY, LIQUID; CYTOCHROME P-450 ENZYME SYSTEM; HUMANS; INHIBITORY CONCENTRATION 50; MAGNOLIA; MICROSOMES, LIVER; NADP; PHENYL ETHERS; TANDEM MASS SPECTROMETRY; URIDINE DIPHOSPHATE GLUCURONIC ACID;

EID: 84877828880     PISSN: 01422782     EISSN: 1099081X     Source Type: Journal    
DOI: 10.1002/bdd.1837     Document Type: Article

References (27)

1. Ito K, Iida T, Ichino K, Tsunezuka M, Hattori M, Namba T,. Obovatol and obovatal, novel biphenyl ether lignans from the leaves of Magnolia obovata Thunb. Chem Pharm Bull(Tokyo) 1982; 30: 3347-3353.
2. Lee YJ, Choi DY, Yun YP, et al,. Ethanol extract of Magnolia officinalis prevents lipopolysaccharide-induced memory deficiency via its antineuroinflammatory and antiamyloidogenic effects. Phytother Res 2012; in press. doi: 10.1002/ptr.4740.
3. Lee M, Kwon BM, Suk K, McGeer E, McGeer PL,. Effects of obovatol on GSH depleted glia-mediated neurotoxicity and oxidative damage. J Neuroimmune Pharmacol 2012; 7: 173-186.
4. Ock J, Han HS, Hong SH, et al,. Obovatol attenuates microglia-mediated neuroinflammation by modulating redox regulation. Br J Pharmacol 2010; 159: 1646-1662.
5. Pyo MK, Lee Y, Yun-Choi HS,. Anti-platelet effect of the constituents isolated from the barks and fruits of Magnolia obovata. Arch Pharm Res 2002; 25: 325-328.
6. Park ES, Lim Y, Lee SH, et al,. Antiplatelet activity of obovatol, a biphenolic component of Magnolia obovata, in rat arterial thrombosis and rabbit platelet aggregation. J Atheroscler Thromb 2011; 18: 659-669.
7. Kwak JH, Lee S, Park ES, et al,. Synthesis and anti-platelet activity of obovatol derivatives. Arch Pharm Res 2011; 34: 1107-1112.
8. Choi NH, Choi GJ, Min BS, et al,. Effects of neolignans from the stem bark of Magnolia obovata on plant pathogenic fungi. J Appl Microbiol 2009; 106: 2057-2063.
9. Seo JJ, Lee SH, Lee YS, et al,. Anxiolytic-like effects of obovatol isolated from Magnolia obovata: involvement of GABA/benzodiazepine receptors complex. Prog Neuropsychopharmacol Biol Psychiatry 2007; 31: 1363-1369.
10. Choi DK, Koppula S, Suk K,. Inhibitors of microglial neurotoxicity: focus on natural products. Molecules 2011; 16: 1021-1043.
11. Lee SK, Kim HN, Kang YR, et al,. Obovatol inhibits colorectal cancer growth by inhibiting tumor cell proliferation and inducing apoptosis. Bioorg Med Chem 2008; 16: 8397-8402.
12. Lee SY, Cho JS, Yuk DY, et al,. Obovatol enhances docetaxel-induced prostate and colon cancer cell death through inactivation of nuclear transcription factor-kappaB. J Pharmacol Sci 2009; 111: 124-136.
13. Lee SY, Yuk DY, Song HS, et al,. Growth inhibitory effects of obovatol through induction of apoptotic cell death in prostate and colon cancer by blocking of NF-kappaB. Eur J Pharmacol 2008; 582: 17-25.
14. Bohmdorfer M, Maier-Salamon A, Taferner B, et al,. In vitro metabolism and disposition of honokiol in rat and human livers. J Pharm Sci 2011; 100: 3506-3516.
15. Zhu L, Ge G, Zhang H, et al,. Characterization of hepatic and intestinal glucuronidation of magnolol: application of the relative activity factor approach to decipher the contributions of multiple UDP-glucuronosyltransferase isoforms. Drug Metab Dispos 2012; 40: 529-538.
16. Yoon YJ, Liu KH,. Potential of hydroxyebastine and terfenadine alcohol to inhibit the human cytochrome p450 2J2 isoform. J Korean Soc Appl Biol Chem 2011; 54: 659-666.
17. Kim MJ, Kim H, Cha IJ, et al,. High-throughput screening of inhibitory potential of nine cytochrome P450 enzymes in vitro using liquid chromatography/tandem mass spectrometry. Rapid Commun Mass Spectrom 2005; 19: 2651-2658.
18. Caldentey X, Pericàs MA,. Phosphinite thioethers derived from chiral epoxides. Modular P,S-ligands for Pd-catalyzed asymmetric allylic substitutions. J Org Chem 2010; 75: 2628-2644.
19. Narender M, Reddy MS, Nageswar YVD, Rama Rao K,. Highly regioselective C(3) opening of an aromatic 2,3-epoxy alcohol with sodium phenoxides or thiophenoxides (=benzenethiolates) supported by β-cyclodextrin in water. Helv Chim Acta 2007; 90: 1107-1111.
20. Abaee MS, Mojtahedi MM, Abbasi H, Fatemi ER,. Additive-free thiolysis of epoxides in water: a green and efficient regioselective pathway to b-hydroxy sulfides. Synth Commun 2008; 38: 282-289.
21. Barahman M, Mohammad SB,. Stereo- and regioselective thiolysis of 1,2-epoxides in water. Synth Commun 2007; 37: 3239-3244.
22. Kim H, Kang S, Kim H, et al,. In vitro metabolism of a new cardioprotective agent, KR-32570, in human liver microsomes. Rapid Commun Mass Spectrom 2006; 20: 837-843.
23. Kim H, Yoon YJ, Kim H, et al,. In vitro metabolism of a new cardioprotective agent, KR-33028 in the human liver microsomes and cryopreserved human hepatocytes. Arch Pharm Res 2005; 28: 1287-1292.
24. Walsky RL, Obach RS,. Verification of the selectivity of (+)N-3-benzylnirvanol as a CYP2C19 inhibitor. Drug Metab Dispos 2003; 31: 343.
25. Foti RS, Wahlstrom JL,. CYP2C19 inhibition: the impact of substrate probe selection on in vitro inhibition profiles. Drug Metab Dispos 2008; 36: 523-528.
26. Ko JW, Sukhova N, Thacker D, Chen P, Flockhart DA,. Evaluation of omeprazole and lansoprazole as inhibitors of cytochrome P450 isoforms. Drug Metab Dispos 1997; 25: 853-862.
27. Walsky RL, Gaman EA, Obach RS,. Examination of 209 drugs for inhibition of cytochrome P450 2C8. J Clin Pharmacol 2005; 45: 68-78.